Literature DB >> 2374915

Steroid induced glaucoma: a report of two cases with a review of morbidity and prescribing in general practice.

R P Phillips1, I C McLean, R J Taylor, J V Forrester.   

Abstract

An eight-week general practice based prospective study was carried out to determine the incidence and prevalence of various eye conditions and the frequency of prescription of different topical eye preparations. The most frequently diagnosed eye conditions were infectious conjunctivitis (35%), glaucoma (16%), allergic conjunctivitis (11%), and keratoconjunctivitis sicca (9%). Betamethasone was the fourth most commonly prescribed preparation (9%). Eye preparations containing steroids accounted for 14% of prescriptions. Two cases of steroid induced glaucoma are presented as an illustration of the potential hazards of these preparations. The pathogenesis of steroid induced glaucoma is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2374915     DOI: 10.1177/003693309003500306

Source DB:  PubMed          Journal:  Scott Med J        ISSN: 0036-9330            Impact factor:   0.729


  3 in total

Review 1.  The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.

Authors:  Gerd Geerling; Joseph Tauber; Christophe Baudouin; Eiki Goto; Yukihiro Matsumoto; Terrence O'Brien; Maurizio Rolando; Kazuo Tsubota; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

2.  Corticosteroids and open-angle glaucoma in the elderly: a population-based cohort study.

Authors:  Michael W Marcus; Rogier P H M Müskens; Wishal D Ramdas; Roger C W Wolfs; Paulus T V M De Jong; Johannes R Vingerling; Albert Hofman; Bruno H C Stricker; Nomdo M Jansonius
Journal:  Drugs Aging       Date:  2012-12       Impact factor: 3.923

3.  Facial eczema and sight-threatening glaucoma.

Authors:  Jonathan J Ross; Aby Jacob; Mark Batterbury
Journal:  J R Soc Med       Date:  2004-10       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.